ERES IV
Overview
ERES IV is a private equity fund managed by Edmond de Rothschild Private Equity (France), focusing on mid-sized companies in Europe and North America. The fund primarily invests in sectors such as healthcare, biotechnology, pharmaceuticals, e-commerce, and financial services, targeting companies with established operations and growth potential. ERES IV's investment strategy emphasizes partnerships with management teams to drive long-term value creation, with investments ranging from €10 million to €60 million per transaction. The fund has a strong track record, achieving a gross multiple of 2.3x on invested capital across 35 exited investments, and maintains a low loss rate on invested capital, aided by conservative leverage compared to the market. ERES IV is affiliated with the Edmond de Rothschild Group, benefiting from its brand and culture of risk management and ESG principles.
Investment Focus
- Mid-sized companies in Europe and North America
- Established operations with growth potential
- Sectors: healthcare, biotechnology, pharmaceuticals, e-commerce, financial services
Portfolio Companies
Reach ERES IV directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about ERES IV
What sectors does ERES IV invest in?
ERES IV invests in Financial Services, Healthcare, E-commerce, Pharmaceuticals and Biotechnology, and is based in Île-De-France, France. ERES IV is listed as a private equity in the ConnectSafely investor database.
What stage does ERES IV invest at?
ERES IV backs companies at Early Stage, Growth, Late Stage and Buyout, writing cheques of 10M - 60M.
Which regions does ERES IV invest in?
ERES IV invests across United States, United Kingdom, Canada, France and Netherlands.
What companies has ERES IV invested in?
ERES IV's portfolio includes Alliance Pharma, Oncodesign Services and ZoBio.
Last updated · Source: ConnectSafely investor database
